Formulation & Process Development of Targeted LNPs for In Vivo T Cell & Hematopoietic Stem Cells Editing
2:10 pm - Thursday 1st October 2026
- Establishing robust process characterization strategies for LNP formulation and fill-finish operations to enable consistent product quality through Phase II/III and commercial manufacturingSharing approaches to scale microfluidic mixing and downstream purification workflows while maintaining critical quality attributes including particle size, encapsulation efficiency, and potency
- Aligning analytical methods, comparability packages, and control strategies with evolving global regulatory expectations for commercial mRNA therapeutics and vaccines
